{"id":"NCT00048581","sponsor":"Bristol-Myers Squibb","briefTitle":"Phase III Study of BMS-188667 (CTLA4Ig) in Patients With Rheumatoid Arthritis Who Are Currently Failing Anti-TNF Therapy or Who Have Failed Anti-TNF Therapy in the Past.","officialTitle":"A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 in Subjects With Active Rheumatoid Arthritis on Background Disease Modifying Anti-Rheumatic Drugs (DMARDS) Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2002-12","primaryCompletion":"2009-09","completion":"2009-09","firstPosted":"2002-11-13","resultsPosted":"2011-06-23","lastUpdate":"2011-11-21"},"enrollment":738,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"Abatacept","otherNames":["Orencia","BMS-188667","CTLA4Ig"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Abatacept","otherNames":["Orencia","BMS-188667","CTLA4Ig"]}],"arms":[{"label":"Abatacept","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Abatacept (Long Term)","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this clinical research study is to determine whether abatacept treatment on a background of Disease Modifying Antirheumatic Drugs (DMARDs) will relieve the symptoms of rheumatoid arthritis (RA) in participants who are currently receiving anti-tumor necrosis factor (TNF) therapy for at least 3 months and are not responding or have taken anti-TNF therapy in the last 3 months and did not respond. The safety of treatment with abatacept will also be evaluated. This study also has a 4.5-year long-term extension beginning 6 months after the start of the study.","primaryOutcome":{"measure":"Double-blind Period (DB); Number of Participants With American College of Rheumatology (ACR) 20 Response at Day 169","timeFrame":"Day 169","effectByArm":[{"arm":"Abatacept (ABA)","deltaMin":129,"sd":null},{"arm":"Placebo (PLA)","deltaMin":26,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":8},"locations":{"siteCount":42,"countries":["United States"]},"refs":{"pmids":["18402714","29329602"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":136,"n":317},"commonTop":["UPPER RESPIRATORY TRACT INFECTION","HEADACHE","NASOPHARYNGITIS","BRONCHITIS","SINUSITIS"]}}